The largest group of Black physicians, thought leaders, and celebrities were in one room to have a needed discussion about HIV.

Analysts expect Gilead Sciences to report an earnings per share (EPS) of $1.95. Investors in Gilead Sciences are eagerly ...

Patients with HIV had lower adherence to pre-exposure prophylaxis (PrEP) if they lived in areas with the lowest disadvantage.

Scientific breakthroughs are fueling new hope in women’s health. But experts warn that persistent gaps in funding and access could stall that progress.

Q2 earnings are scheduled to be released on August 7, after market close. The pharma company is expected to post an EPS of $1 ...

On track for proof-of-concept Phase 1b data no later than this fall in participants with recurrent genital herpes for long-acting herpes simplex virus (HSV) helicase-primase inhibitor candidates, ...